Vividion Therapeutics, Inc. is a small‑molecule drug discovery company focused on hard‑to‑drug protein targets in oncology and immunology. Spun out of Scripps Research and based in San Diego, California, it applies chemoproteomics and mass‑spectrometry–based screening to map ligandable sites across the proteome and identify selective covalent and non‑covalent ligands.
The company’s platform integrates covalent fragment screening, advanced analytical chemistry, and structure‑guided medicinal chemistry to generate orally bioavailable compounds against targets such as transcription factors, E3 ligases, and other historically challenging proteins. Vividion’s pipeline centers on cancer and inflammatory diseases. Since 2021, it has been a wholly owned subsidiary of Bayer AG, operating as an independent unit within Bayer’s pharmaceuticals organization.
None yet. When a new project in the record names Vividion Therapeutics as owner, partner or investor, it shows here.
Randomized Phase II will test VVD-214 plus pembrolizumab versus pembrolizumab alone as first‑line treatment for advanced MSI‑high/dMMR colorectal cancer, enrolling ~140 patients.
